MedTrace Logo

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

NCT03197298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2062

Last updated 2017-06-23

No results posted yet for this study

Summary

Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin). This change is based on studies that showed benefits of ticagrelor. However, study participants were only partly treated by percutaneous coronary intervention (PCI). In patients who were treated by PCI, this was generally performed using of bare metal or first-generation drug-eluting stents (DES).

CHANGE DAPT is an investigator-initiated, prospective, single centre registry, in which we evaluate the impact of the guideline suggested change in the primary DAPT regimen (from clopidogrel to ticagrelor) on 1-year clinical outcome in ACS patients treated by PCI with newer-generation DES in the Thoraxcentrum Twente.

Conditions

  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention
  • Drug-Eluting Stents

Interventions

DRUG

Clopidogrel

DRUG

Ticagrelor

Sponsors & Collaborators

  • Thorax Centrum Twente

    lead OTHER

Principal Investigators

  • Clemens von Birgelen, MD,PhD,Prof · Thoraxcentrum Twente

  • K. Gert van Houwelingen, MD · Thoraxcentrum Twente

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-21
Primary Completion
2016-07-25
Completion
2016-07-25

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03197298 on ClinicalTrials.gov